Discover Our Mission

Innovating Neurological Research

At Abdelhak Lab, we leverage state-of-the-art biomarker technologies to bridge the gap between clinical practice and research, focusing on advancing the understanding of neurological conditions like multiple sclerosis.

technology

ELISA (Enzyme-Linked Immunosorbent Assay)

ELISA is a classic and widely utilized immunoassay technique that detects and quantifies target proteins, peptides, or antibodies through specific antigen-antibody interactions. It employs an enzyme-conjugated detection antibody and a colorimetric, fluorescent, or chemiluminescent substrate to produce a measurable signal proportional to the analyte level. ELISA is known for its robustness, relative simplicity, and versatility across a wide range of applications, making it a staple in clinical diagnostics and research laboratories.

ECL (Electrochemiluminescence) Assay

Electrochemiluminescence (ECL) assays harness an electrical stimulus to excite a luminescent label on detection antibodies, generating a light signal that is directly proportional to the amount of target present. Platforms like MSD (Meso Scale Discovery) use this approach to offer high sensitivity, wide dynamic range, and low background noise. The electrochemiluminescent readout is particularly advantageous for multiplexing, allowing researchers to simultaneously measure multiple analytes in a single sample.

Simoa (Single Molecule Array)

Simoa technology revolutionizes immunoassays by enabling the detection of individual protein molecules through a digital readout system. This ultrasensitive approach traps individual beads—each capturing a single target molecule—within thousands of micro-wells and uses fluorescence to detect positive signals one bead at a time. As a result, Simoa delivers exceptionally low limits of detection and precise quantification for biomarkers, making it invaluable in translational research and early disease detection.

Olink PEA (Proximity Extension Assay)

Olink’s Proximity Extension Assay (PEA) leverages pairs of antibodies linked to unique DNA oligonucleotides, which hybridize only when the antibody pair binds in close proximity to the target protein. The resulting DNA duplex is amplified and quantified using real-time PCR or next-generation sequencing methods. This process enables highly specific and multiplexed protein measurements, providing detailed protein profiling in limited sample volumes with excellent sensitivity and specificity.

Collaborators

Publications

  1. Vitamin B12 Levels Association with Functional and Structural Biomarkers of Central Nervous System Injury in Older Adults. Ann Neurol. 2025 Feb 10. 
  2. Multifaceted Biomarkers Suggest a Similar Profile of CNS Pathology in Relapsing and Progressive MS. Eur J Neurol. 2025 Feb
  3. Association of Menopause With Functional Outcomes and Disease Biomarkers in Women With Multiple Sclerosis. Neurology. 2025 Jan 28
  4. Increased EBNA1-specific antibody response in primary-progressive multiple sclerosis. J Neurol. 2024 Dec 12
  5. Proteomic Profiling and Pathophysiological Implications in Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2025 Jan
  6. Remyelination protects neurons from DLK-mediated neurodegeneration. Nat Commun. 2024 Oct 23
  7. Serum Glial Fibrillary Acidic Protein and Neurofilament Light Chain Levels Reflect Different Mechanisms of Disease Progression under B-Cell Depleting Treatment in Multiple Sclerosis. Ann Neurol. 2024 Oct 16.
  8. Remyelination protects neurons from DLK-mediated neurodegeneration. bioRxiv. 2024 Aug 31
  9. Association of Complement Factors With Disability Progression in Primary Progressive Multiple Sclerosis. Neurol Neuroimmunol Neuroinflamm. 2024 Jul
  10. Targeting complement C3a receptor resolves mitochondrial hyperfusion and subretinal microglial activation in progranulin-deficient frontotemporal dementia. bioRxiv. 2024 Jun 01.
  11. An autoantibody signature predictive for multiple sclerosis. Nat Med. 2024 May
  12. Neurofilaments as biomarkers in neurological disorders – towards clinical application. Nat Rev Neurol. 2024 05
  13. Serum biomarker levels predict disability progression in patients with primary progressive multiple sclerosis. J Neurol Neurosurg Psychiatry. 2024 Apr 12
  14. Synaptic injury in the inner plexiform layer of the retina is associated with progression in multiple sclerosis. Cell Rep Med. 2024 Apr 16
  15. Scientific commentary on: “Phosphorylated tau in the retina correlates with tau pathology in the brain in Alzheimer’s disease and primary tauopathies”. Acta Neuropathol. 2024 02 03
  16. Serum glial fibrillary acidic protein and disability progression in progressive multiple sclerosis. Ann Clin Transl Neurol. 2024 02
  17. Neurofilament Light Chain Elevation and Disability Progression in Multiple Sclerosis. JAMA Neurol. 2023 12 01
  18. Patient-reported outcome parameters and disability worsening in progressive multiple sclerosis. Mult Scler Relat Disord. 2024 Jan
  19. Serum neurofilament light chain reference database for individual application in paediatric care: a retrospective modelling and validation study. Lancet Neurol. 2023 09
  20. Editorial: CSF and blood biomarkers in COVID-19 and other neuroinfectious diseases. Front Neurol. 2023
  21. Challenges and Opportunities for the Promising Biomarker Blood Neurofilament Light Chain. JAMA Neurol. 2023 06 01
  22. Prognostic performance of blood neurofilament light chain protein in hospitalized COVID-19 patients without major central nervous system manifestations: an individual participant data meta-analysis. J Neurol. 2023 Jul
  23. A Predictive Autoantibody Signature in Multiple Sclerosis. medRxiv. 2023 May 15
  24. Visually Evoked Potential as Prognostic Biomarker for Neuroaxonal Damage in Multiple Sclerosis From a Multicenter Longitudinal Cohort. Neurol Neuroimmunol Neuroinflamm. 2023 05
  25. Serum Glial Fibrillary Acidic Protein Compared With Neurofilament Light Chain as a Biomarker for Disease Progression in Multiple Sclerosis. JAMA Neurol. 2023 03 01
  26. The multifaceted role of neurofilament light chain protein in non-primary neurological diseases. Brain. 2023 02 13

Get Involved with Our Research

Contact us today to learn more about our groundbreaking studies and collaborations.

Scroll to Top